SCHEMBL2128457

SCHEMBL2128457

COC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 17/20 0.72
LONP1 P36776 11/20 0.72
PSMB8 P28062 11/20 0.72
PSMB9 P28065 11/20 0.72
PSMB6 P28072 11/20 0.72
PSMB10 P40306 11/20 0.72
PSMB11 A5LHX3 10/20 0.72
PSMA7 O14818 10/20 0.72
PSMB1 P20618 10/20 0.72
PSMA1 P25786 10/20 0.72
PSMA2 P25787 10/20 0.72
PSMA3 P25788 10/20 0.72
PSMA4 P25789 10/20 0.72
PSMA5 P28066 10/20 0.72
PSMB4 P28070 10/20 0.72
PSMB3 P49720 10/20 0.72
PSMB2 P49721 10/20 0.72
PSMA6 P60900 10/20 0.72
PSMA8 Q8TAA3 10/20 0.72
PSMB7 Q99436 10/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913564 1.00 PSMB5 (0.72) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL2127966 0.96 PSMB5 (0.69) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL2126526 0.93 LONP1 (0.70) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL5383178 0.91 PSMB5 (0.69) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL1913443 0.91 PSMB5 (0.76) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL2125752 0.91 PSMB5 (0.76) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL23133178 0.91 PSMB5 (0.68) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL12521571 0.89 PSMB5 (0.74) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL9941415 0.89 PSMB5 (0.71) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL2127762 0.89 PSMB5 (0.73) PSMB5LONP1PSMB8PSMB9PSMB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210088504-A1 PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) 2021-03-25 US disclosed
EP-2444411-B1 TRIPEPTIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF UNIV BEIJING (CN) 2016-10-26 EP disclosed
US-9421237-B2 Tripeptide boronic acid or boronic ester, preparative method and use thereof PEKING UNIVERSITY (CN) 2016-08-23 US disclosed
US-8895497-B2 Cathepsin S inhibitors DCB-USA, LLC (US) 2014-11-25 US disclosed
US-20120135921-A1 TRIPETIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF PEKING UNIVERSITY (CN) 2012-05-31 US disclosed
EP-2444411-A1 TRIPEPTIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF Peking University (CN) 2012-04-25 EP disclosed
US-20110166141-A1 CATHEPSIN S INHIBITORS DCB-USA, LLC (US) 2011-07-07 US disclosed
WO-2011069149-A2 CATHEPSIN S INHIBITORS DCB-USA LLC (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210088504-A1 PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF SENP8, SENP6, SENP7 PSMB5 106/4885LONP1 423/4885PSMB8 43/4885
US-20120135921-A1 TRIPETIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF BTD, PSMB11, IAPP PSMB5 12/4885LONP1 274/4885PSMB8 29/4885
US-20110166141-A1 CATHEPSIN S INHIBITORS CTSS, CTSV, CTSB PSMB5 371/4885LONP1 867/4885PSMB8 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.